HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

9-methoxy-2-methylellipticinium acetate

a potential inhibitor of the AKT pathway; structure in first source

Also Known As:

API-59CJ-OMe

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Buttin, Barbara M: 1 article (03/2008)
2.	Hardt, Jennifer L: 1 article (03/2008)
3.	Hoekstra, Anna V: 1 article (03/2008)
4.	Kim, J Julie: 1 article (03/2008)
5.	Lurain, John R: 1 article (03/2008)
6.	Schink, Julian C: 1 article (03/2008)
7.	Singh, Diljeet K: 1 article (03/2008)
8.	Ward, Erin C: 1 article (03/2008)
9.	Cao, Y: 1 article (11/2004)
10.	Chen, J: 1 article (11/2004)

Related Diseases

1.	Endometrial Neoplasms (Endometrial Cancer) 03/01/2008 - "Treatment with 6 microM API-59CJ-OME resulted in preferential cell death in Ishikawa and RL95 cells compared to another endometrial cancer cell line, ECC1 after 48 h of treatment. " 11/15/2004 - "API-59CJ-OMe may therefore have therapeutic potential for those endometrial cancers that harbour PTEN mutations and AKT activation."
2.	Neoplasms (Cancer) 07/08/1994 - "9-Methoxy-2-methylellipticinium acetate (6), along with the 9-methyl and 9-chloro derivatives (7, and 8, respectively) have shown remarkable selectivities in vitro against the NCI human CNS cancer subpanel. "